Aditya K Gupta, Mary A Bamimore, Vasiliki Economopoulos, Mesbah Talukder, Vincent Piguet, Renata Magalhaes
{"title":"A network meta-analysis study of monotherapies for hidradenitis suppurativa: analyses of the current evidence base.","authors":"Aditya K Gupta, Mary A Bamimore, Vasiliki Economopoulos, Mesbah Talukder, Vincent Piguet, Renata Magalhaes","doi":"10.1080/09546634.2025.2513054","DOIUrl":"10.1080/09546634.2025.2513054","url":null,"abstract":"<p><strong>Background: </strong>The number of monotherapies for hidradenitis suppurativa (HS) has expanded. However, the efficacy of active comparators has not been determined in head-to-head trials.</p><p><strong>Aims: </strong>We conducted an NMA to determine the relative efficacy and safety of monotherapies for HS.</p><p><strong>Methods: </strong>The literature was systematically reviewed to obtain data from trials that (1) were published in English, (2) investigated a systemically administered monotherapy with an immunomodulatory agent (3) randomized, and (4) quantified efficacy, at 16 weeks, insofar as the Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50), Dermatology Life Quality Index (DLQI) and Numeric Rating Scale 30 (NRS30). For safety, we analyzed the occurrence of treatment-emergent adverse events (TEAEs). For sensitivity analyses, we conducted network meta-regressions adjusted for age and sex.</p><p><strong>Results: </strong>We determined the efficacy of numerous regimens including those approved by the United States FDA; for instance, the FDA-approved 'bimekizumab 320 mg every 2 weeks' was more efficacious than 'IFX-1 800 mg every 2 weeks' (odd ratio = 1.99, 95% credible interval: 1.09,3.87, <i>p</i> < 0.05) in terms of HiSCR-50. Sensitivity analyses showed that the main analyses were robust. Overall, risk of bias across studies was low.</p><p><strong>Conclusions: </strong>The current NMA provides comparative evidence on systematic immunomodulatory HS monotherapies from the most up-to-date trial evidence.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2513054"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rapid and sustained response to tofacitinib in a patient with anal pyoderma gangrenosum under immunosuppression and bone marrow suppression.","authors":"Yuting Zhou, Long Zhang, Wenhui Wang","doi":"10.1080/09546634.2025.2555193","DOIUrl":"https://doi.org/10.1080/09546634.2025.2555193","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the therapeutic efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of refractory perianal pyoderma gangrenosum (PG) under conditions of baseline immunosuppression and bone marrow suppression.</p><p><strong>Methods: </strong>We present a 62-year-old male with a 4-month history of painful, progressive symmetrical perianal ulcerations diagnosed as PG, coexisting with condyloma acuminatum. The patient had a background of pure red cell aplasia and myasthenia gravis, and was undergoing chronic immunosuppressive therapy with prednisolone and tacrolimus. Previous interventions including topical agents, antibiotics, phototherapy, and surgical debridement were ineffective. Oral tofacitinib (5 mg/day) was introduced following multidisciplinary evaluation.</p><p><strong>Results: </strong>Marked pain reduction was achieved by day two of tofacitinib therapy, with near-complete ulcer healing observed within two weeks. Hematologic parameters remained stable throughout the 4-month treatment course, which was well tolerated with no adverse effects. The patient remained relapse-free during a 1-year follow-up.</p><p><strong>Conclusions: </strong>Tofacitinib may offer a rapid, effective, and well-tolerated treatment alternative in cases of refractory PG, even when layered onto preexisting immunosuppressive regimens. This case highlights the potential of JAK inhibitors as targeted therapy in complex PG presentations and supports their further clinical evaluation.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2555193"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mariko Niki, Masahiro Kamata, Yayoi Tada, Yoshiaki Kubo
{"title":"Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.","authors":"Mariko Niki, Masahiro Kamata, Yayoi Tada, Yoshiaki Kubo","doi":"10.1080/09546634.2025.2555684","DOIUrl":"https://doi.org/10.1080/09546634.2025.2555684","url":null,"abstract":"<p><strong>Objectives: </strong>Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.</p><p><strong>Methods: </strong>We analyzed data from 27 AA patients treated with baricitinib at our hospital.</p><p><strong>Results: </strong>The majority (81%) had alopecia universalis, with a mean baseline SALT score of 93.9. Disease duration was positively correlated with the current AA episode's duration and negatively with serum TARC levels. At 3, 6, 9, and 12 months, 3.8%, 19.2%, 37%, and 58% of patients achieved a SALT score ≤20, respectively. The duration of the current AA episode at initiating baricitinib was correlated positively with absolute SALT score at 6 and 9 months, and negatively with the reduction rate of SALT score at 6 and 9 months. A shorter duration of the current episode (<4 years) was associated with better improvement in SALT scores at 6, 9, and 12 months compared to longer durations (≥4 years).</p><p><strong>Conclusions: </strong>Baricitinib proved effective and safe for severe AA patients. The duration of the current AA episode is a key predictor of treatment success, highlighting the importance of early intervention.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2555684"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Topical treatment adherence and writing clarity: insights from a precision dispenser study.","authors":"Sabine L Abukhadra, Robin C Yi, Steven R Feldman","doi":"10.1080/09546634.2025.2529387","DOIUrl":"https://doi.org/10.1080/09546634.2025.2529387","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2529387"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial.","authors":"Kejian Zhu, Qiaoli Zheng, Yingjie Zhu, Xia Wu, Hao Cheng","doi":"10.1080/09546634.2025.2560505","DOIUrl":"10.1080/09546634.2025.2560505","url":null,"abstract":"<p><strong>Background: </strong>Vunakizumab (anti-interleukin-17A antibody) has shown favorable efficacy and safety in treating moderate-to-severe plaque psoriasis. The morbidity and severity of psoriasis vary in different regions of China.</p><p><strong>Objective: </strong>This post-hoc exploratory analysis aims to investigate the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China.</p><p><strong>Methods: </strong>This post-hoc exploratory analysis used data from a phase III trial (NCT04839016), with 461 patients receiving vunakizumab categorized into North (<i>n</i> = 118), Central (<i>n</i> = 252), and South (<i>n</i> = 91) China groups.</p><p><strong>Results: </strong>Psoriasis area and severity index (PASI)75/90/100 and static physician's global assessment (sPGA) 0/1 response rates were similar among the three groups at week 12 (W12). Additionally, W12-W52 sustained PASI 75/90/100 and sPGA 0/1 response rates were also similar among groups. Similar improvements in patient-reported outcomes, including dermatology life quality index, itch-numerical rating scale, EuroQol-5D, and short form-36, were observed in the three groups. The incidence of adverse events was 80.5%, 90.1%, and 90.1% in the North, Central, and South China groups, respectively.</p><p><strong>Conclusion: </strong>The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2560505"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tofacitinib successful treatment of idiopathic twenty-nail dystrophy: a case report.","authors":"Wenjun Zhao, Shijun Shan, Dongmei Liu","doi":"10.1080/09546634.2025.2562314","DOIUrl":"https://doi.org/10.1080/09546634.2025.2562314","url":null,"abstract":"<p><strong>Purpose: </strong>Twenty-nail dystrophy (TND) is a chronic nail disorder affecting all or some nails and posing a significant therapeutic challenge for dermatologists. Janus kinase (JAK) inhibitors have recently emerged as a promising treatment modality for refractory nail diseases.</p><p><strong>Results: </strong>We report a case of a patient with idiopathic TND for 12 years duration, and successfully treated with oral tofacitinib, which offered a potential new therapeutic choice for this challenging entity. Some successful cases of treating inflammatory nail diseases with Janus kinase (JAK) inhibitors were reviewed.</p><p><strong>Conclusion: </strong>Janus kinase (JAK) inhibitors may be a promising therapeutic option for patients with twenty-nail dystrophy.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2562314"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Baseline hair loss severity as a potential confounder in studies on minoxidil and low-level laser therapy.","authors":"Amir Reza Akbari, Benyamin Alam, Ahmed Ageed","doi":"10.1080/09546634.2025.2506673","DOIUrl":"https://doi.org/10.1080/09546634.2025.2506673","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2506673"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe.","authors":"S Ständer, D Thaçi","doi":"10.1080/09546634.2024.2438803","DOIUrl":"10.1080/09546634.2024.2438803","url":null,"abstract":"<p><p><b>Background:</b> Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.</p><p><p><b>Objective:</b> While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.</p><p><p><b>Methods:</b> This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.</p><p><p><b>Results:</b> Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.</p><p><p><b>Conclusion:</b> Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438803"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli
{"title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).","authors":"D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli","doi":"10.1080/09546634.2025.2452948","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452948","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452948"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Successful treatment of Kimura's disease with dupilumab and review of dupilumab in treating eosinophilic dermatoses.","authors":"Yunhong Zheng, Suju Luo","doi":"10.1080/09546634.2024.2449153","DOIUrl":"https://doi.org/10.1080/09546634.2024.2449153","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2449153"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
